Matthews A, et al. - In women with a history of non-metastatic breast cancer, researchers studied the impact of endocrine therapies on a wide range of clinical cardiovascular disease outcomes. The results from this systematic review suggest that, in tamoxifen users vs both non-users and aromatase inhibitor users, there is an increased risk of venous thromboembolism. Data also indicated a higher risk of vascular diseases, myocardial infarction, and angina in aromatase inhibitor users vs tamoxifen users, which might be driven by a protective effect of tamoxifen.